The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Background The consensus molecular subtypes (CMSs) of colorectal cancer (CRC) capture
tumor heterogeneity at the gene-expression level. Currently, a restricted number of …

Transforming growth factor-beta (TGF-β) signaling is one of the important cellular pathways
that play key roles for tissue maintenance. In particular, it is important in the context of …

Over the last decades, transcriptome profiling emerged as one of the most powerful
approaches in oncology, providing prognostic and predictive utility for cancer management …

Current staging systems of cancer are mainly based on the anatomical extent of disease.
They need refinement by biological parameters to improve stratification of patients for tumor …

Background FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or
bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients …

Colorectal cancer (CRC) is one of the most prevalent cancers, with more than one million
new cases every year. In the last few decades, several advancements in therapeutic and …

Colon cancer inter-tumour heterogeneity is installed on multiple levels, ranging from (epi)
genetic driver events to signalling pathway rewiring reflected by differential gene expression …

Abstract The Colorectal Cancer Subtyping Consortium identified four gene expression
consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and …

Colorectal cancer (CRC) is the second leading cause of cancer death worldwide that is
attributed to gradual long‐term accumulation of both genetic and epigenetic changes. To …